Introduction
Mammalian prions (PrP Sc ) are proteinaceous infectious agents that consist of misfolded, self-replicating states of a sialoglycoprotein called the prion protein or PrP C [1, 2] . Mammalian prions replicate by recruiting and converting PrP C molecules expressed by a host into misfolded PrP Sc states [3] . PrP C is a sialoglycoprotein, in which sialic acid residues are linked to the terminal positions of its two N-linked glycans [4] [5] [6] . Conversion of sialylated PrP C into PrP Sc gives rise to sialylated PrP Sc [7, 8] . The fact that PrP C and PrP Sc are sialylated was discovered more than 30 years ago [9] , yet this finding and the role of sialylation in pathogenesis of prion diseases has not been investigated [10] . The mammalian immune system uses terminal sialylation of glycoproteins to recognize host cells and set them apart from pathogenic microorganisms [11] . The presence of terminal sialic acids on glycans serves as part of a 'self-associated molecular pattern', whereas the lack of terminal sialylation, which exposes a terminal galactose, sets up a 'pathogen-associated molecular pattern'. Moreover, decline in sialic acid content represents one of the molecular signatures of 'apoptotic-cell-associated molecular patterns' found in apoptotic or aging cells [12, 13] . Removal of sialic acids from cell surface glycans exposes galactose residues that generate 'eat me' signals for professional and nonprofessional macrophages [14] [15] [16] [17] . Previously, we proposed that sialylation of PrP Sc glycans prevents the innate immune system and microglia from recognition of prions as potential pathogens and that sialylation controls PrP Sc fate in an organism [18] [19] [20] [21] . In support of this hypothesis, we showed that PrP Sc with reduced sialylation levels does not induce prion disease in wild-type animals when administered via intracranial or intraperitoneal injections [19] [20] [21] . Moreover, we also showed that prion infectivity could be switched off and on in a reversible manner via removing and then reinstalling sialylation of N-linked glycans [19] . Finally, sialylation was found to be involved in PrP Sc trafficking and its sequestration by secondary lymphoid organs (SLOs) including spleen and lymph nodes [20] . As the sialylation status of PrP Sc is important to prion pathogenesis, dissecting the cellular mechanisms that control sialylation of PrP Sc might open new approaches for controlling or treating prion disease.
In glycoproteins, sialic acid residues can be attached to galactose or N-acetylgalactosamine of glycans via alpha 2,3-, 2,6-, 2,8-, or 2,9-linkages [22] . In PrP C and PrP Sc , sialic acids were found to be linked to the terminal positions of the two N-linked glycans via alpha 2,3-or 2,6-linkages [4] [5] [6] further referred to as 2,3-and 2,6-linkages or 2,3-and 2,6-sialylation. Among 20 sialyltransferases expressed in mammals, two sialyltransferase families, ST3Gal and St6Gal, are responsible for linking sialic acids to galactose via 2,3-or 2,6-bonds, respectively [23] . Because the relative percentage of 2,3-versus 2,6-linked sialic acids in PrP C and PrP Sc is not known, the relative impact of ST3Gal and St6Gal in determining sialylation status of PrP C and PrP Sc is difficult to define. In the current work, we found that in N-linked glycans of PrP Sc , the sialic acid residues are predominantly 2,6-linked. High percentages of 2,6-linked sialic acids were observed in PrP Sc from brain, spleen, or cultured cells and in three prion strains. Moreover, the variation in the ratio of 2,3-versus 2,6-linked sialic acid was found to be relatively minor between brain-, spleen-, or cell-derived PrP Sc suggesting that the type of linkage is independent of its source. Based on the current results, we proposed that sialylation status of PrP Sc is controlled predominantly by sialyltransferases of St6Gal family.
Results
Sialidase assay for analysis of sialic acid linkages Two groups of sialyltransferases are responsible for sialylating N-linked glycans of glycoproteins: ST3Gal and ST6Gal. Members of ST3Gal family attach sialic acid residues to galactose via a 2,3-linkage, whereas ST6Gal group attaches via a 2,6-linkage. To evaluate the percentage of 2,3-versus 2,6-linked sialic acid residues in PrP Sc , we employed bacterial sialidases characterized by different specificities. Sialidase from Streptococcus pneumoniae (SP) is known to be highly specific and only cleaves sialic acids attached via 2,3-linkages. In contrast, sialidases from Clostridium perfringens (CP) or Arthrobacter ureafaciens (AU) have broad specificity and cleave sialic acids regardless of their linkages.
To validate the specificity of sialidases, bovine serum fetuin was treated with SP, CP, or AU sialidases. Fetuin was used because it is a highly silaylated protein containing~15 sialic acid residues per protein molecule, and its ratio of 2,3-versus 2,6-linked sialic acids is estimated to be approximately 1 : 1 [24] . As judged from the electrophoretic mobility in SDS/ PAGE, enzymatic treatment with all three sialidases reduced the molecular weight of fetuin, a fact consistent with the cleavage of sialic acid residues (Fig. 1A) . To verify the specificity of enzymes, serial threefold dilutions of mock-treated or SP-, CP-or AU-treated fetuin samples were loaded onto dot blots and stained with the following lectins: SNA (specific to terminal 2,6-linked sialic acids), MAL-II (specific to terminal 2,3-linked sialic acids), or Peanut Agglutinin lectin (PNA; specific to terminal asialo Galb1-3GalNAc) (Fig. 1B,C) . As expected, treatment of fetuin with SP did not reduce the intensity of SNA staining, as compared with mock-treated fetuin. This result confirms the lack of cleavage of 2,6-linked sialic acids by SP. Instead, the intensity of MAL-II staining, which is specific for 2,3-linked sialic acids, was reduced significantly (Fig. 1B,C) . Staining with PNA confirmed the appearance of terminal galactose residues in SP-treated fetuin (Fig. 1B,C) . In contrast to SP-treated fetuin, CP-and AU-treated samples showed decreases in signal intensity in SNA and MAL-II staining, confirming broad specificity of these sialidases. In parallel, the intensity of PNA staining increased to a similar degree for both CP-and AU-treated fetuin (Fig. 1B,C) . In summary, these results confirm the narrow specificity of SP and the broad specificity of CP and AU sialidases. Because CP and AU showed very similar pattern, only AU will be used for analysis of PrP Sc .
Brain-derived PrP Sc is predominantly 2,6-sialylated
To investigate the type of sialic acid linkage in PrP Sc , three mouse-adapted strains (22L, RML, ME7) were employed. For each strain, samples of denatured brain-derived PrP Sc were treated with SP or AU sialidase or mock-treated and then analyzed by 2D gel electrophoresis with subsequent western blots. The vertical dimension of 2D separates individual PrP molecules according to their glycosylation status (from top to bottom, respectively): di-, mono-, and unglycosylated polypeptides. The distribution of molecules in the horizontal dimension reflects their sialylation status (Fig. 2) [21, 25] . Hypersialylated molecules run toward acidic pHs, while hyposialylated run toward basic pHs. Due to structural heterogeneity of the GPI anchors [26, 27] , unglycosylated PrPs also showed several charge isoforms.
A shift of distribution toward basic pH in sialidase-treated samples implies a loss of sialic acids due to enzyme cleavage. For all three strains, the SP sialidase produced only a minimal shift of di-and monoglycosylated charge isoforms toward basic pH, as compared with the mock-treated samples ( Fig. 2A) . In contrast, the AU sialidase produced a massive shift of di-and monoglycosylated charge isoforms to basic pI ( Fig. 2A) . A shift toward basic pI upon treatment with AU sialidase was also observed for unglycosylated isoforms, which is attributed to a cleavage of a single sialic acid residue on GPI anchor. These data argue that brain-derived PrP Sc contain predominantly 2,6-linked sialic acids in all three mouse-adapted strains.
Spleen-derived PrP
Sc is predominantly 2,6-sialylated
To test whether the type of sialic acid linkage is tissuespecific, spleen-derived PrP Sc from mice infected with 22L strain were treated with SP or AU sialidases. Again, very little shift in distribution of charge isoforms toward basic pH, if any, was observed upon treatment with SP sialidases (Fig. 2B) . In contrast, treatment with AU sialidase resulted in a substantial shift of di-and monoglycosylated isoforms toward basic pH (Fig. 2B) . While the efficiency of enzymatic treatment of spleen-derived PrP Sc appeared to be lower than that of brain-derived PrP Sc , which was presumably due to very low amount of PrP Sc relative to total glycoproteins in spleen, the responses to SP and AU sialidases were very similar to that of brain-derived PrP Sc .
N2a cell-derived PrP Sc is predominantly 2,6-sialylated
To test whether the type of sialic acid linkage is altered in PrP Sc produced in vitro in cultured cells, N2a cell-derived RML and 22L strains were analyzed. Consistent with previous studies [27] , PrP Sc generated in N2a cells showed a lower proportion of hyposialylated molecules relative to brain-derived PrP Sc (compare top panels in Fig. 2A and C). These differences could be attributed to the higher expression levels of sialyltransferases and/or a more complex structure for N-linked glycans of PrP expressed in N2a cells relative to those in a brain. Treatment with SP sialidase of N2a cell-derived PrP Sc resulted in a moderate shift of diglycosylated charge isoforms toward basic pH for both strains (Fig. 2C ). Treatment with AU sialidase resulted in dramatic shift of both di-and monoglycosylated charge isoforms (Fig. 2C ). In fact, upon SP treatment, the charge distributions of di-and monoglycosylated isoforms were identical to that of unglycosylated isoforms arguing that complete cleavage of sialic acid residues from N-linked glycans was achieved.
Staining with lectins confirmed that brainderived PrP
To verify that PrP Sc has predominantly 2,6-linked sialic acids using an alternative technique, PrP Sc was purified from brain of animals infected with RML, 22L, or ME7. Purified PrP Sc was analyzed by western blots followed by staining with the following lectins: SNA, which is specific for 2,6-linked sialic acid, or MAL-II, which is specific for 2,3-linked sialic acid. Serial dilutions of fetuin from bovine serum were used as a reference and positive control for lectin staining. SNA readily stained purified brain-derived PrP Sc for all three strains (Fig. 3A) . The signal intensity for RML, 22L, or ME7 was higher than that of 100 lgÁmL À1 fetuin but lower than 1000 lgÁmL
À1
fetuin. Using recombinant PrP as internal control for loading, we estimated that the gel loading of our purified PrP Sc contained between 50 and 500 lgÁmL À1 of PrP Sc ( Fig. 3B) , which was consistent with the SNA staining intensity. None of the brain-derived materials of the three strains showed signals on blot staining with MAL-II lectin (Fig. 3C ). Although MAL-II is known to have a lower affinity than SNA, MAL-II did detect 100 lgÁmL À1 fetuin on the same blot ( Fig. 3C ). To prove that PrP Sc was transferred successfully onto the membrane treated with MAL-II, the membrane was re-stained with anti-PrP antibody Ab3531 (Fig. 3C lower panel) . Restaining confirmed that the transfer was successful. Due to differences in binding affinities between SNA and MAL-II, it might be difficult to estimate precisely the amounts of 2,3-versus 2,6-linked sialic acids in PrP Sc via lectin staining. Nevertheless, these results are consistent with the data on sialidase treatment and indicate that there is considerably less 2,3-linked sialic acid on PrP Sc than 2,6-linked sialic acid.
C1, the proteolytic fragment of PrP C , is predominantly 2,6-sialylated What is the mechanism behind predominant sialylation of PrP Sc via 2,6-linkages? Does PrP Sc recruit predominantly 2,6-sialylated PrP C selectively, at the expense of 2,3-sialylated PrP C ? As an alternative mechanism, does predominant 2,6-linkages in PrP Sc simply reflect predominantly 2,6-sialylation linkage in PrP C ? To answer these questions, the sialylation linkage of PrP C has to be analyzed. Our previous studies showed that PrP C is poorly resolved on 2D, presumably due to the peculiar properties of the octarepeat region [27, 28] . In the absence of a reliable method for analysis of fulllength PrP C isoforms, we used the C1 fragment of PrP C as a reporter for assessing the type of sialylation linkage in PrP C . C1 is a C-terminal proteolytic fragment of PrP C that lacks the octarepeat region, has the same ratio of di-, mono-, and unglysocylated isoforms as PrP C , and is well-resolved on 2D. Denatured samples of brain homogenates from healthy mice or N2a cells lysates were treated with SP or AU sialidases and analyzed by 2D. In both brain-and N2a-derived C1, a minor shift of the charge distribution toward basic side of the 2D gel was observed upon treatment with SP sialidase compared with the mock-treated controls (Fig. 4) . AU sialidase produced a much more significant shift in comparison to SP sialidase. Again, this result argues that the N-linked glycans on the C1 proteolytic fragments are sialylated predominantly via 2,6-linkages in both mouse brain and N2a cells (Fig. 4) .
Quantification of 2,3-and 2,6-linked sialic acid residues
To quantify the percentage of 2,3-and 2,6-linked sialic acid residues, the sum intensity of charge isoforms remaining after sialidase treatment was quantified by densitometry and compared to those of corresponding mock-treated controls. It is likely that this approach underestimates the total amounts of 2,3-and 2,6-linked sialic acid residues, because the efficiency of sialidase treatment is expected to be less than 100%. Nevertheless, assuming that both sialidases exhibit similar efficiency in cleavage within the same tissue-or cell-derived material but distinct specificity, this procedure assesses the relative contribution of 2,3-versus 2,6-linked sialic acid residues. Treatment with broad specificity sialidase AU removed most of the sialic acid, although relatively minor amounts of remaining sialylated glycoforms were found in all samples (Figs 2 and 5) . The highest amount of sialylated glycoforms was observed in the spleenderived PrP Sc , whereas the lowest amounts were found in N2a-derived PrP Sc and brain-or N2a-derived C1 (Fig. 5) . These results suggest that the tissues/cell type determines the efficiency of cleavage of sialic acid residues, although the effect of tissues or cells on cleavage efficiency was modest. In contrast to AU, treatment with SP removed only a minor fraction of sialic acid residues in PrP Sc or C1 arguing that PrP Sc and C1 have predominantly 2,6-linked sialic acids (Figs 2, 4, and 5 ). The differences in composition of 2,3-versus 2,6-linked sialic acids between the three strains were not statistically significant, with 22L showing the largest contribution of 2,3-linked residues among three strains. Brainderived and N2a-derived PrP Sc showed a similar trend in the composition of the linkage type.
Discussion
This study established that in N-linked glycans of PrP Sc , the sialic acid residues are predominantly 2,6-linked.
High percentages of 2,6-linked sialic acids were observed in PrP Sc of three prion strains, as well as PrP Sc from brain, spleen, or cells cultured in vitro. Moreover, the variation in the ratio of 2,3-versus 2,6-linked sialic acid was found to be relatively minor between brain-, spleen-, or cell-derived PrP Sc , suggesting that the type of linkage is independent of tissue type but appears to be controlled by the protein and/or its N-linked glycans. Based on the current results, one might speculate that in a wild-type host, the tissue-or cell-specific levels of expression of ST3Gal versus ST6Gal sialyltransferases might have only limited impact on the percentage of 2,3-versus 2,6-linked sialic acid on a particular glycoprotein.
In previous studies, we showed that PrP C is recruited into PrP Sc selectively in a strain-specific manner, according to the sialylation status of PrP C Nlinked glycans [25, 29] . While some strains are capable of accommodating PrP C molecules with heavily sialylated glycans showing minimal selectivity, others preferentially select PrP C with low levels of glycan sialylation at the expense of molecules with heavily sialylated glycans [25, 29] . It appears that this was not the case with respect to the type of sialic acid linkage. To address the question on selectivity of recruitment according to the linkage type, the proteolytic fragment C1 was used as a reporter of sialylation status of PrP C , because sialoglycoforms of PrP C are not resolved well on 2D gels [28] . The current work found that the percentage of 2,3-versus 2,6-linked sialic acid in PrP C proteolytic fragment C1 resembles those of PrP Sc . Nevertheless, these results should be considered with caution, because the extent to which sialylation linkage of C1 reflects that of PrP C is not known. fragment in normal brain homogenates (NBH) or N2a cell lysates treated with SP (middle panels, green) or AU (bottom panels, blue) sialidases or mock-treated (top panels, red). Western blots were stained with SAF-84 anti-PrP antibodies. Black triangles, white triangles, and arrows mark di-, mono-, and non-glycosylated glycoforms, respectively. The dash line arbitrary divides hypersialylated and hyposialylated C1 isoforms. Material from three C57black mice or three independent cell culture experiments was analyzed for each treatment condition.
Our previous studies proposed that sialylation of PrP Sc N-linked glycans plays an important role in controlling the fate of prions in an organism [18, 21] . In support of this hypothesis, we showed that animals inoculated with PrP Sc with reduced sialylation levels via intracranial or intraperitoneal routes lack any clinical or subclinical signs of prion disease, live healthy lives, and have undetectable levels of PrP Sc [19] [20] [21] . Considering that the sialylation status of PrP Sc is essential for determining its fate, it is important to investigate the cellular mechanisms that one can target for manipulating sialylation status of PrP C and PrP Sc . This study was undertaken to assess the type of linkage by which sialic acid residues are attached to galactose. Answering this question is important for several reasons described below.
First, identification of linkage type helps to narrow down the range of sialyltransferases responsible for sialylating PrP C . In a cell, sialylation is controlled by two groups of enzymes, sialyltransferases that transfer sialic acid residues to glycans and neuraminidases that cleave sialic acid residues. Previously, we showed that knocking out neuraminidases 1, 3, or 4 that are expressed on a cell surface and/or in lysosomes did not affect the steady-state sialylation levels of PrP C in mice, presumably due to the fast degradation of desialylated PrP C [28] . Instead, a general inhibitor of sialyltransferases was found to reduce the sialylation levels of PrP C in N2a cells, suggesting that modulating the activity of sialyltransferases instead of neuraminidases is more effective for controlling the sialylation status of PrP C [28] . However, in the absence of knowing the linkage type, identification of primary sialyltransferase would be difficult, because mammals express 20 sialyltransferases. Out of 20, five sialyltransferases exhibit substrate specificity for sialylation of N-linked glycans via 2,3-or 2,6-linkages, three of which belong to the ST3Gal family (ST3Gal3, ST3Gal4, and ST3Gal6) and two of which belong to the ST6Gal family (ST6Gal1, ST6Gal2). The results of the current work suggest that out of 20 mammalian sialyltransferases, the ST6Gal family that consists of ST6Gal1 and ST6Gal2 is likely to contribute the most to sialylation of PrP C and PrP Sc . ST6Gal1 is expressed throughout the organism, including the CNS. ST6Gal2 is expressed exclusively in the brain, predominantly during embryonic development [30] . This expression profile suggest that ST6Gal1 is the main contributor to sialylation of N-linked glycans in the periphery and CNS, which is consistent with the previous studies of global sialylation using ST6Gal1 null mice [31] . In summary, this study argues that ST6Gal1 should be considered the most useful target for manipulating sialylation status of PrP C and PrP Sc . Second, knowledge about the type of sialylation linkage might contribute to the identification of potential binding partners of PrP
Sc that recognize carbohydrate epitopes. Several classes of carbohydrate-binding proteins, including C-type lectins, galectins, siglecs and selectins, are expressed in CNS and bind to their partners via sialylated carbohydrate epitopes displaying preferences for 2,3-, 2,6-, or 2,8-linked sialic acids [32] . As the majority of sialic acid residues are 2,6-linked, the current work narrows down the range of possible carbohydrate-binding proteins that might interact with PrP Sc via N-linked glycans. Third, the observation that PrP Sc is predominantly 2,6-sialylated might shed new light on possible mechanisms responsible for prion lymphotropism. Upon . The amount of sialic acid residues in corresponding mock-treated samples (red bars) was taken as 100%. The percentage of sialic acid residues was analyzed from 2D gels as described in Materials and methods. Data are presented as means AE SD, n = 3 independent brain, spleen, or cell samples.
peripheral exposure, PrP Sc colonizes SLOs, including spleen and lymph nodes, where it replicates autonomously from the CNS [33] [34] [35] [36] . While the molecular mechanism behind lymphotropism of prions is not known, PrP Sc colonization of SLOs is very important, because it precedes invasion of the CNS [37] [38] [39] and because SLOs are more permissive to prions acquired via cross-species transmission than the CNS [40] . Moreover, SLOs represent silent reservoirs of prion infection, where PrP Sc could hide undetected for a life-time while possibly imposing a high risk of transmission through blood donation [41, 42] . Our recent studies revealed that the sialylation status of PrP Sc was critical for its effective trafficking to SLOs [20] . Within several hours following peripheral exposure of mice to prions, PrP Sc with unaltered sialylation status was found to be sequestered by spleen and lymph nodes, whereas partially desialylated PrP Sc was found predominantly in liver [20] . Notably, N-linked glycans sialylated via 2,6-linkages were shown to be responsible for directed trafficking and selective adhesion of hepatocarcinoma cells to SLOs [43, 44] . Another study that employed synthetic glycoclusters demonstrated that in circulation, the glycoclusters with 2,6-linked sialic residues were more stable and showed slower clearance rates in comparison to glycoclusters with 2,3-linkages [45] . Drawing a parallel between these studies, one might speculate that the lymphotropism and stability of PrP Sc in the periphery is attributable to 2,6-linked sialic acid residues of PrP Sc N-linked glycans. Crystallographic studies suggest that structural differences between 2,3-and 2,6-linked sialic acids exists. Oligosaccharides with 2,6-linked sialic acid were found to be more conformationally flexible than those with 2,3 links, and this flexibility is believed to influence oligosaccharide binding to hemagglutinin of influenza virus [46] , for example. 2,3-linked sialic acid with its underlying galactose was shown to form a more tightly packed cone-like topology, whereas the Neu5Aca2-6Gal motif adopts both cone-like and umbrella-like shapes [46] . The latter shape is believed to expose a larger portion of the glycan surface, as well as provide space for additional sialic acid modifications. When situated on longer and more branched glycans, the 2,6-linked sialic acid bearing oligosaccharides tend to prefer umbrella-like over cone-like shapes. The fact that PrP Sc is mostly 2,6-sialylated suggests a more substantial exposure of terminal carbohydrate epitopes toward potential binding partners, with not only sialic acid but also the underlying sugars playing a role in the interactions, in comparison to glycoproteins with predominantly 2,3-sialylated glycans.
Materials and methods

Ethics statement
This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The animal protocol was approved by the Institutional Animal Care and Use Committee of the University of Maryland, Baltimore (assurance no. A32000-01, permit no. 0215002).
Preparation of brain and spleen material
Brains or spleens were collected from mice at the terminal stage of the disease. Ten percent (w/v) scrapie brain or spleen homogenates were prepared individually for each animal in PBS using glass/Teflon homogenizers attached to a cordless 12-V compact drill (Ryobi Tools, Anderson, SC, USA) as described previously [47] .
Culturing of N2a cells
N2a cells were cultured at 37°C, 5% CO 2 in minimum essential medium (catalog no. 10-010-CV; Corning, Corning, NY, USA) supplemented with 10% FBS (catalog no. 10437; Life Technologies, Carlsbad, CA, USA), antibiotics (1% v/v penicillin/streptomycin, catalog no. 15140; Life Technologies), and 1% GlutaMAX. For infection with scrapie, N2a cells were grown to 50% confluence and then incubated for 24 h with 0.5% scrapie brain homogenate from RML-or 22L-infected mice. After incubation, the medium was removed and replaced with fresh medium. Cells were then split and passaged eight times to obtain a stable infection. In parallel for controls, uninfected N2a cells were grown under the same conditions.
Treatment of fetuin with sialidases
Bovine fetal serum fetuin (cat no. F3385; Sigma Aldrich, St. Louis, MO, USA) was diluted to 5 mgÁmL À1 in PBS supplied with 1% (v/v) Triton X-100 and denatured by incubating for 10 min at 95°C. For sialidase treatment, after addition of 10% (v/v) sialidase buffer GlycoBuffer1 supplied by the enzyme manufacturer, 500 unitsÁmL À1 of sialidase or an equal volume of water for mock treatment was added, followed by incubation on a shaker at 37°C for 12 h. The sialidases used were from S. pneumoniae (catalog no. P0743L; New England Biolabs, Ipswich, MA, USA), C. perfringens (catalog no. P0720L; New England Biolabs), or A. ureafaciens (catalog no. P0722L; New England Biolabs). After treatment with enzyme, the samples were either heated for 10 min in a boiling water bath and used for dot blot or supplied with 49 SDS buffer, boiled for 10 min, and loaded on a gel.
Treatment of scrapie samples with sialidases
Ten percent (w/v) scrapie brain or spleen material was diluted 10-fold in 19 PBS supplied with 1% (v/v) Triton X-100 and supplemented with 25 lgÁmL À1 PK (catalog no.
P8107; New England Biolabs). After 30 min at 37°C, PK digestion was stopped by addition of 5 mM PMSF. Then, the samples were denatured by incubating for 10 min at 95°C. The subsequent treatment with either S. pneumoniae (catalog no. P0743L; New England Biolabs) or A. ureafaciens sialidase (catalog no. P0722L; New England Biolabs) was as follows. After addition of 10% (v/v) sialidase buffer GlycoBuffer1 supplied by the enzyme manufacturer, either 500 unitsÁmL À1 of sialidase or an equal volume of water for mock treatment was added, followed by incubation on a shaker at 37°C for 12 h. After treatment, 49 SDS buffer was added to the samples, they were boiled for 10 min at 95°C and used for two-dimensional electrophoresis. N2a cells stably infected with scrapie were collected in 200 lL of PBS, lysed by 30 s sonication (Misonix S-4000 equipped with microplate horn; Qsonica, Newtown, CT, USA) in the presence of 1% v/v Triton X-100, and treated with 10 lgÁmL À1 PK (New England Biolabs) for 30 min at 37°C, after which PK digestion was stopped by addition of 5 mM PMSF. The subsequent treatment with sialidases was the same as for brain-and spleen-derived scrapie. After adding 49 SDS loading buffer, brain-, spleen-and cellderived samples were heated for 10 min in a boiling water bath and used for two-dimensional electrophoresis.
Treatment of normal samples with sialidases
Ten percent (w/v) normal brain homogenates were diluted 10-fold in 19 PBS supplied with 1% (v/v) Triton X-100 and denatured by incubating for 10 min at 95°C. The subsequent treatment with sialidases was the same as for scrapie material. Noninfected N2a cells were cultured to 70% confluence, collected in 200 lL of PBS, lysed by 30-s sonication (Misonix S-4000 with microplate horn, Qsonica) in the presence of 1% v/v Triton X-100, and denatured by incubating for 10 min at 95°C. The subsequent treatment with sialidases was the same as for scrapie material. After adding 49 SDS loading buffer, the sample was heated for 10 min in a boiling water bath and used for two-dimensional electrophoresis.
Fetuin dot blot
Fetuin samples treated with sialidases were serially diluted threefold in PBS. Two microliters of each sample was placed on a nitrocellulose membrane, dried for 10 min, and then blocked with 0. 
Gel staining with Coomassie Blue
Fetuin samples treated with sialidases and supplied with 49 SDS buffer were loaded on a gel with a protein weight ladder (cat no LC5925; Thermo Fisher Scientific) for reference. The gel was visualized with Coomassie G-250 and scanned using a FluorChem M system (ProteinSimple).
PrP
Sc purification and analysis by western blot PrP Sc was purified according to a previously published protocol [48] . The purity of scrapie material was assessed by SDS/PAGE followed by silver staining. For western blot with lectins, the resulting brain-derived RML, 22L, and ME7 scrapie materials and serial dilutions of bovine fetuin were loaded on SDS/PAGE gel. After western blotting for 2 h on ice, the membranes were blocked with 0.5 mgÁmL
À1
BSA (cat no A9647; Sigma Aldrich) in PBS-T (PBS supplied with 1% v/v Triton X-100) for 30 min at room temperature with shaking, and then incubated in either SNA (cat no B-1305; Vector Laboratories), MAL-II (cat no B-1265; Vector Laboratories), or PNA (cat no CAC-JOM-J214; Alexis Biochemicals) biotinylated lectins for 1 h at room temperature with shaking. After washing twice for 15 min each time in PBS-T, the membranes were incubated in 1 : 10 000 HRP-Conjugated Streptavidin (cat no. N100; Thermo Fisher Scientific) for 45 min at room temperature with shaking, washed twice for 15 min each in PBS-T, then briefly incubated in Luminata Forte Western HRP substrate (cat no WBLUF0500; Merck Millipore) and visualized using a FluorChem M system (ProteinSimple). For staining or re-staining a blot with anti-PrP antibody, the blot was first blocked in fat-free milk in PBS-T and then incubated in 1 : 5000 Ab3531 (Abcam, Cambridge, UK) for 1 h, washed three times in PBS-T for 10 min, incubated with secondary Goat-Anti-Rabbit (KPL, Milford, MA, USA) at dilution 1 : 5000 for 45 min, washed three times in PBS-T for 10 min, and visualized with Luminata Forte HRP substrate (cat # MIL-WBLUF0500; Merck Millipore). In the case of re-staining, the blot was washed in PBS-T three times for 15 min prior to blocking. For the second dimension, SDS/PAGE was performed for 1 h at 170 V. Immunoblotting was performed as described elsewhere, and blots were stained using Ab3531 antibody for mouse-or cell-derived scrapie material and in SAF-84 for PrP C .
Two-dimensional electrophoresis
Analysis of 2D and dot blots
Two-dimensional western blotting and dot blotting signal intensities were digitized using ALPHAVIEW software (ProteinSimple). For analysis of sialylation status, a previously published procedure was used [25] . Briefly, 2D blots were aligned horizontally and a line drawn at pI 7.5 (pI 5.3 in case of C1 fragments analysis) was used to arbitrarily separate charge isoforms into hypersialylated and hyposialylated. In the software window, a rectangle was drawn to confine the spots of interest, and the densities measured. The intensity of an equal background area from the same blot was subtracted before further analysis. The acquired spot ensemble intensities were used to calculate percentage of hypersialylated isoforms that were defined operationally as isoforms located to the left of the pI 7.5 line. The percentage of hypersialylated isoforms for each sample series was calculated assuming the total intensity of all isoforms as 100%.
For densitometry analysis of dot blots, target spots were selected using a uniform rectangular sampling area that encompassed the spot of interest. Background optical density of an equal area from the same blot was determined and subtracted from the density of the bands. At least three measurements from independent gel loadings were used for each sample for calculating mean and standard deviations. The curves were then plotted in MS Excel.
